Hanmi Science Valuation

Q: What is the Fair Price of A008930 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A008930 (₩33700) is trading above our estimate of [[fair value]] (₩7197.27)

Is A008930 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A008930 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A008930 (₩33700) is trading above our estimate of fair value (₩7197.27)

Significantly Below Fair Value: A008930 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A008930?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A008930. This is calculated by dividing A008930's market cap by their current preferred multiple.
What is A008930's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩2.28t

A008930 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	38.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A008930's PE Ratio compare to its peers?

The above table shows the PE ratio for A008930 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.5x
A128940 Hanmi Pharm	23x	11.9%	₩3.6t
A237690 ST PharmLtd	81.4x	34.2%	₩1.8t
A185750 Chong Kun Dang Pharmaceutical	6.3x	-21.8%	₩1.3t
A069620 Daewoong Pharmaceutical	11.1x	5.0%	₩1.3t
A008930 Hanmi Science	19x	n/a	₩2.3t

Price-To-Earnings vs Peers: A008930 is good value based on its Price-To-Earnings Ratio (19x) compared to the peer average (30.5x).

Price to Earnings Ratio vs Industry

How does A008930's PE Ratio compare vs other companies in the Asian Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: A008930 is good value based on its Price-To-Earnings Ratio (19x) compared to the Asian Healthcare industry average (22.9x).

Price to Earnings Ratio vs Fair Ratio

What is A008930's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A008930 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	19x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A008930's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.